Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G1B | P04054 | 2/20 | 0.58 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 0.58 |
| ▸ | IDO1 | P14902 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10514895 | 0.97 | PLA2G1B (0.56) | PLA2G1BATG4BIDO1THRBCYP3A4 | |
| SCHEMBL12271490 | 0.82 | MAOB (0.61) | KMT2AALDH1A1 | |
| SCHEMBL22129790 | 0.78 | PLA2G1B (0.56) | PLA2G1BATG4BIDO1CYP3A4CYP2D6 | |
| SCHEMBL1796909 | 0.78 | LMNA (0.77) | PLA2G1BATG4BIDO1CYP3A4CYP2D6 | |
| SCHEMBL184001 | 0.78 | LMNA (0.77) | PLA2G1BATG4BIDO1CYP3A4CYP2D6 | |
| SCHEMBL6895044 | 0.76 | THRB (0.59) | IDO1THRBKMT2A | |
| Hydrochloric Acid SCHEMBL6077029 | 0.76 | LMNA (0.74) | PLA2G1BATG4BCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL17122900 | 0.76 | IDO1 (0.55) | PLA2G1BATG4BIDO1CYP3A4CYP2D6 | |
| SCHEMBL17065246 | 0.76 | THRB (0.59) | IDO1THRBCYP3A4CYP2C19LMNA | |
| SCHEMBL1777533 | 0.76 | PLA2G1B (0.54) | PLA2G1BATG4BIDO1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2902382-A1 | Primary hydroxylamines and uses thereof | Fundació Institut de Recerca Biomèdica IRB (Barcelona) (ES) | 2015-08-05 | — | — | EP | claimed |
| US-20040110729-A1 | Primary N-hydroxylamines | NIH | 2004-06-10 | — | — | US | claimed |
| US-6455589-B1 | AN ORALLY ADMINISTRABLE EFFECTIVE UNIT SOLID DOSAGE OF A PRIMARY N-HYDROXYLAMINE OR A SALT, FREE OF NITRONE; USEFUL FOR REDUCING OXIDATIVE DAMAGE OR DELAYING SENESCENCE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-09-24 | — | — | US | claimed |
| US-12129221-B2 | Difluoro phenyl amide RIP1 inhibitor | SIRONAX LTD (KY) | 2024-10-29 | — | — | US | disclosed |
| CN-113272272-B | RIP1 inhibitors | 圣瑞诺有限公司 | 2023-04-07 | — | — | CN | disclosed |
| EP-3883918-A1 | RIP1 INHIBITORS | Sironax Ltd (KY) | 2021-09-29 | — | — | EP | disclosed |
| US-20210284598-A1 | RIP1 Inhibitors | SIRONAX LTD (KY) | 2021-09-16 | — | — | US | disclosed |
| CN-113272272-A | RIP1 inhibitors | 圣瑞诺有限公司 | 2021-08-17 | — | — | CN | disclosed |
| EP-3168219-B1 | PYRIDONE DERIVATIVE HAVING TETRAHYDROPYRANYL METHYL GROUP | DAIICHI SANKYO CO LTD (JP) | 2021-03-31 | — | — | EP | disclosed |
| US-10954225-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-23 | — | — | US | disclosed |
| US-10954225-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-23 | — | — | US | disclosed |
| US-7507838-B2 | Process for the preparation of Z-5-carboxymethylene-1,3-dioxolan-4-ones | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-24 | — | — | US | disclosed |
| US-20080268537-A1 | PRIMARY N-HYDROXYLAMINES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-10-30 | — | — | US | disclosed |
| WO-2007015775-A2 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| US-6906046-B2 | Pharmaceutical uses and synthesis of benzobicyclooctanes | CELLTECH R & D INC. (US) | 2005-06-14 | — | — | US | disclosed |
| US-20030069305-A1 | Pharmaceutical uses and synthesis of benzobicyclooctanes | CELLTECH R & D, INC. | 2003-04-10 | — | — | US | disclosed |
| US-6455589-B1 | AN ORALLY ADMINISTRABLE EFFECTIVE UNIT SOLID DOSAGE OF A PRIMARY N-HYDROXYLAMINE OR A SALT, FREE OF NITRONE; USEFUL FOR REDUCING OXIDATIVE DAMAGE OR DELAYING SENESCENCE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-09-24 | — | — | US | disclosed |
| WO-2002051851-A2 | PHARMACEUTICAL USES AND SYNTHESIS OF BENZOBICYCLOOCTANES | CELLTECH R & D, INC. (US) | 2002-07-04 | — | — | WO | disclosed |
| EP-0310061-A1 | 5-Mono or Disubstituted-3-(phenyl or 2-naphthalenyl)-3-[(1H-imidazol-1-ylmethyl) or (1H-1,2,4-triazol-1-ylmethyl)]-2-(methyl or benzyl)isoxazolidines | FISONS CORPORATION (US) | 1989-04-05 | — | — | EP | disclosed |
| US-4749793-A | 5-substituted-3-phenyl-3-[1H-imidazol-1-ylmethyl) or (1H-1,2,4-triazol-1-ylmethyl]-2-benzylisoxazolidines (ir 3011) | PENNWALT CORPORATION (US) | 1988-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284598-A1 | RIP1 Inhibitors | RIPK1, RIPK3, RIPK4 | PLA2G1B 3694/4885ATG4B 1030/4885IDO1 832/4885 |
| US-20030069305-A1 | Pharmaceutical uses and synthesis of benzobicyclooctanes | CXCL8, CASP8, IL18 | PLA2G1B 2348/4885ATG4B 1935/4885IDO1 2479/4885 |
| US-10954225-B2 | Selective NR2B antagonists | GRIN2B, GRIN2A, GRIN1 | PLA2G1B 3207/4885ATG4B 4630/4885IDO1 4175/4885 |
| US-12129221-B2 | Difluoro phenyl amide RIP1 inhibitor | RIPK1, RIPK3, RIPK4 | PLA2G1B 3150/4885ATG4B 1449/4885IDO1 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.